Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CALITHERA BIOSCIENCES, INC.

(CALA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Calithera Biosciences : Buys Two Clinical-Stage Assets from Takeda to Boost Oncology Pipeline -- Stock Up 3% After-Hours

10/18/2021 | 04:48pm EST


ę MT Newswires 2021
All news about CALITHERA BIOSCIENCES, INC.
11/12Calithera to Present at the 2021 Jefferies London Healthcare Conference
AQ
11/09CALITHERA : Q3 Earnings Snapshot
AQ
11/09CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
11/09Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlight..
PU
11/09Investor Deck
PU
11/09Calithera Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
11/09Earnings Flash (CALA) CALITHERA BIOSCIENCES Posts Q3 Revenue $6.8M
MT
11/09Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlight..
AQ
11/08Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
AQ
11/08Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
AQ
More news
Analyst Recommendations on CALITHERA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 9,79 M - -
Net income 2021 -62,4 M - -
Net cash 2021 65,0 M - -
P/E ratio 2021 -0,86x
Yield 2021 -
Capitalization 54,8 M 54,8 M -
EV / Sales 2021 -1,04x
Capi. / Sales 2022 54,8x
Nbr of Employees 93
Free-Float 99,2%
Chart CALITHERA BIOSCIENCES, INC.
Duration : Period :
Calithera Biosciences, Inc. Technical Analysis Chart | CALA | US13089P1012 | MarketScreener
Technical analysis trends CALITHERA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 0,73 $
Average target price 1,83 $
Spread / Average Target 150%
EPS Revisions
Managers and Directors
Susan M. Molineaux President, Chief Executive Officer & Director
Stephanie Wong Secretary, Chief Financial & Accounting Officer
Francesco Parlati Senior Vice President-Research
Susan B Demo Vice President-Medical Affairs
Emil T. Kuriakose Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CALITHERA BIOSCIENCES, INC.-85.09%55
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.78%63 017
VERTEX PHARMACEUTICALS-13.24%52 137